These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 1958490)

  • 1. Characterization of murine monoclonal antibodies directed against the Kell blood group glycoprotein.
    Jaber A; Loirat MJ; Willem C; Bloy C; Cartron JP; Blanchard D
    Br J Haematol; 1991 Oct; 79(2):311-5. PubMed ID: 1958490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A murine monoclonal antibody against Kx protein which reacts also with beta-spectrin.
    Carbonnet F; Blanchard D; Hattab C; Cochet S; Petit-Leroux Y; Loirat MJ; Cartron JP; Bertrand O
    Transfus Med; 2000 Jun; 10(2):145-54. PubMed ID: 10849386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Production of a new murine monoclonal antibody with Fy6 specificity and characterization of the immunopurified N-glycosylated Duffy-active molecule.
    Riwom S; Janvier D; Navenot JM; Benbunan M; Muller JY; Blanchard D
    Vox Sang; 1994; 66(1):61-7. PubMed ID: 8146985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the blood group Kell (K1) antigen with a human monoclonal antibody.
    Jaber A; Blanchard D; Goossens D; Bloy C; Lambin P; Rouger P; Salmon C; Cartron JP
    Blood; 1989 May; 73(6):1597-602. PubMed ID: 2713497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunochemical characterization of the human blood cell membrane glycoprotein recognized by the monoclonal antibody 12E7.
    Latron F; Blanchard D; Cartron JP
    Biochem J; 1987 Nov; 247(3):757-64. PubMed ID: 2447875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunochemical analysis of the Kx protein from human red cells of different Kell phenotypes using antibodies raised against synthetic peptides.
    Carbonnet F; Hattab C; Collec E; Le van Kim C; Cartron JP; Bertrand O
    Br J Haematol; 1997 Mar; 96(4):857-63. PubMed ID: 9074432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRIC 18: a monoclonal antibody with a specificity related to the kell blood group system.
    Parsons SF; Judson PA; Anstee DJ
    J Immunogenet; 1982 Dec; 9(6):377-80. PubMed ID: 7161507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of monoclonal antibodies directed against Fy3, Jra, Lub, Kell or Kell related antigens.
    Janvier D; Veaux S; Benbunan M
    Transfus Clin Biol; 1997; 4(1):107-9. PubMed ID: 9095513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in red cell ion transport, reduced intratumoral neovascularization, and some mild motor function abnormalities accompany targeted disruption of the Mouse Kell gene (Kel).
    Zhu X; Rivera A; Golub MS; Peng J; Sha Q; Wu X; Song X; Kumarathasan P; Ho M; Redman CM; Lee S
    Am J Hematol; 2009 Aug; 84(8):492-8. PubMed ID: 19544475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transfusion of murine red blood cells expressing the human KEL glycoprotein induces clinically significant alloantibodies.
    Stowell SR; Girard-Pierce KR; Smith NH; Henry KL; Arthur CM; Zimring JC; Hendrickson JE
    Transfusion; 2014 Jan; 54(1):179-89. PubMed ID: 23621760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Another example of a KEL1 variant red cell phenotype due to a threonine to serine change at position 193 of Kell glycoprotein.
    Lee-Stroka H; Slezak SL; Adams S; Martin J; Robbins FM; Caruccio L; Byrne KM; Stroncek DF
    Transfusion; 2008 May; 48(5):925-9. PubMed ID: 18248571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A KEL gene encoding serine at position 193 of the Kell glycoprotein results in expression of KEL1 antigen.
    Poole J; Warke N; Hustinx H; Taleghani BM; Martin P; Finning K; Crew VK; Green C; Bromilow I; Daniels G
    Transfusion; 2006 Nov; 46(11):1879-85. PubMed ID: 17076841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal anti-K14 and anti-K2.
    Nichols ME; Rosenfield RE; Rubinstein P
    Vox Sang; 1987; 52(3):231-5. PubMed ID: 3300028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of cytomegalovirus glycoproteins in a family of complexes designated gC-II with murine monoclonal antibodies.
    Kari B; Goertz R; Gehrz R
    Arch Virol; 1990; 112(1-2):55-65. PubMed ID: 2164376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new low-incidence antigen in the Kell blood group system: VLAN (KEL25).
    Jongerius JM; Daniels GL; Overbeeke MA; Petty AC; Reid M; Oyen R; Rijksen H; van Leeuwen EF
    Vox Sang; 1996; 71(1):43-7. PubMed ID: 8837356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation and characterization of a new monoclonal antibody CAF7 specific for a leukocyte activation antigen.
    Pashov AD; Taskov HB
    Hybridoma; 1994 Jun; 13(3):229-36. PubMed ID: 7927367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Production and characterization of anti-kell monoclonal antibodies using transfected cells as the immunogen.
    Chu TH; Yazdanbakhsh K; Oyen R; Smart E; Reid ME
    Br J Haematol; 1999 Sep; 106(3):817-23. PubMed ID: 10468879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies against Kell glycoprotein: serology, immunochemistry and quantification of antigen sites.
    Parsons SF; Gardner B; Anstee DJ
    Transfus Med; 1993 Jun; 3(2):137-42. PubMed ID: 7690639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p32, a platelet autoantigen recognized by an SLE-derived autoantibody that inhibits platelet aggregation.
    Xu H; Frojmovic MM; Wong T; Rauch J
    J Autoimmun; 1995 Feb; 8(1):97-119. PubMed ID: 7734040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel KEL*1,3 allele with weak Kell antigen expression confirming the cis-modifier effect of KEL3.
    Körmöczi GF; Scharberg EA; Gassner C
    Transfusion; 2009 Apr; 49(4):733-9. PubMed ID: 19347978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.